Health Advances’ Post

The #celltherapy landscape continues to evolve rapidly, and the launch of the first #TIL therapy only heightens the effort to bring these important therapeutic options to patients. In our latest blog, my colleagues discuss the opportunities and challenges facing developers. #CGT #healthadvances #ASCGT #oncology

The announcement of FDA’s #oncology dose optimization initiative, #ProjectOptimus, is a long-coming step towards improving dosing of targeted oncology therapies. With this initiative, the #FDA extends guidance on clinical trial design for targeted therapies. While these guidelines should improve patient safety and QOL, the long-term implications for the commercialization of anticancer drugs are still unfolding. In our most recent blog, we discuss the potential commercial ramifications of Project Optimus, drawing on recent analogs including #lumakras, and highlight the possible impacts on the targeted therapy pipeline. Read here: https://bit.ly/3K752r9 Vivek Mittal, Gary Gustavsen, Ned Wydysh, Earl Gillespie, Arpit Dave, Ph.D., Ashley Peake

The Nordlandssykehuset HF hospital trust in Norway has published a noteworthy paper on the implementation of digital patient monitoring in routine care. The paper emphasizes the importance of addressing barriers and leveraging facilitators, along with utilizing established implementation frameworks, as critical factors for a successful implementation. For more insights, you can access the full paper at the following link: https://lnkd.in/d6ahAyQy.

Excited to announce that APPERTURE HEALTH will be presenting our latest research at #ISPOREurope! Join us at Poster EE184 on Monday, Nov 18, 2024 | 16:00 - 19:00 for a discussion on The European Pricing Landscape for Targeted Therapies in Advanced or Metastatic Non-Small Cell Lung Cancer! We look forward to meeting you and discussing our research. #HEOR #MarketAccess #Pricing #NSCLC #HealthcareResearch #LifeSciences #AmplifyingValue #AppertureInsights

Join us for the third dialogue in WHAM's 3Not30 Virtual Roundtable Series, as we focus on accelerating research, innovation, and investment in women's health over the next three years!    This month, we're turning our attention to autoimmune disease. With autoimmune disease disproportionately affecting women, comprising 80% of patients, it is crucial to address the substantial gaps in awareness, funding, and innovation surrounding these chronic conditions. Esteemed leaders in this field will delve into the current landscape and unveil our ambitious goals for the next three years.   🔗 REGISTER NOW: https://lnkd.in/e6ZUetb2   📆 Date: Thursday, March 14th, 2024 ⏰ Time: 1-2 pm ET   The call for change in 3Not30 is here, and together, we actively shape the future of women’s health. Don't miss this opportunity to be a part of the conversation and drive meaningful impact! ⁠ Thank you to everyone who contributed to the creation of the 3Not30 goals:  Michael Annichine (Magee-Womens Research Institute & Foundation), Tom Cassels (Rock Health), Dr. Janine Austin Clayton (The National Institutes of Health), Esther Dyson (Wellville), Jessica J. Federer, Laurie Fenton Ambrose (GO2 for Lung Cancer), Dr. Lori Frank (The New York Academy of Medicine), Maria C. Freire, Ph.D., Dr. Elizabeth Garner (Ferring Pharmaceuticals; American Medical Women's Association (AMWA)), Dr. Julie Gerberding (Foundation for The National Institutes of Health), Stacy Pagos Haller (BrightFocus Foundation), Marsha Henderson (FDA), Dr. Hadine Joffe, MD MSc (Brigham and Women's Hospital; Harvard Medical School), Sasha Kelemen (Leerink Partners), Sheila Ann Mikhail (Asklepios BioPharmaceutical, Inc. (AskBio)), Melissa Gong Mitchell (Global Coalition on Aging), Dr. Stacey E. Rosen, MD, FACC, FACP, FAHA (Northwell Health), Dr. Erica Ollmann Saphire (La Jolla Institute for Immunology), Ashraf (Ash) Shehata (KPMG), Dr. Ellen Sigal (Friends of Cancer Research), Ramita Tandon (Walgreens)   #WHAMnow #3Not30 #WomensHealth #HeartHealth #Research #Innovation #Investment #VirtualRoundtable #HealthcareFuture

Pfizer Australia held a special installment of its Pfizer Invites thought leadership symposium yesterday, bringing together some of Australia’s top health leaders for a discussion on the Health Technology Assessment Review final report, with a specific focus on the challenges of implementation. Anne Harris, Pfizer ANZ Managing Director and Medicines Australia Deputy Chair, was joined by Professor Andrew Wilson AO, Co-Director of the Leeder Centre for Health Policy and former PBAC Chair; Martin Bowles AO PSM, National CEO Calvary Health Care and former Secretary Department of Health; Liz de Somer, CEO of Medicines Australia; and Sharon Winton, CEO of Lymphoma Australia. The event provided a valuable opportunity to share ideas and drive conversation about improving patient access to new innovative medicines. #HTAReform #StrongerPBS

#NCDs,#healthfinancing, #integratedcare. The countdown to the 2025 UN High Level Meetings on NCDs and mental health begins this month. Health financing is currently one of the biggest challenges for advancing NCDs and mental health in LMICs. Join us for a discussion during the Consortium of Universities for Global Health virtual week for a discussion with experts on how to advance health financing for essential, integrated NCD management.

Happy Clinical Trials Day! 🎉 Today we celebrate the dedicated scientists, researchers and healthcare professionals who contribute to groundbreaking health studies globally. We honor the patients and participants who play a vital role in advancing health research. We recognise the dedicated teams that work tirelessly, pushing boundaries to enhance patient outcomes and shape health policies. Our incredible trials team is currently running nine randomized controlled trials (RCTs) in general practice testing novel interventions covering cancer prevention, risk-based screening, pharmacogenomics, and early cancer diagnosis in primary care 💪🏼 It is essential to continue advocating for the importance of clinical trials in enhancing patient care. Photo features (from top left to right): Dr Sibel Saya, Prof Jon Emery, Dr Dulashi (Anna) Withanage Dona, Georgia Ramsay, Sophie Chima, Eliza Zmislja, A/Prof Jennifer McIntosh, Dr Javiera Martinez Gutierrez She/Her, Floriana La Rocca, Matt Thoenig, Afaf Humam, Madeline Luke and Sandra Sursock #HealthResearch #PatientCare. #ClinicalTrials #HealthcareInnovation #ClinicalTrialsDay #CTD2024

YES TO LIFE ANNUAL CONFERENCE 2024 - 28th September  “PUSHING THE BOUNDARIES” Get your tickets for the early bird price of £35 for our in person conference in Central London on September 28th. The title is ‘Pushing the Boundaries’, as we have decided to devote the Conference to looking at the latest developments in Integrative Medicine, across the board. So that includes new techniques, new scientific understandings, and new applications for existing therapies, and you’ll be hearing fresh insights from some of your most trusted clinicians and scientists, and led into unfamiliar territory by pioneering speakers who may be as yet unfamiliar. The conferences are being co-created by Patricia Peat from Cancer Options and the @peatinstitute and Yes to Life, with the aim of sending our audiences home with a wealth of resources on which to be able to draw for their own needs. If you go to the Conference website, you can see the topics that each of our expert speakers will be discussing. Plus there will be an Exhibition hall with stands that will offer yet more knowledge and resources to delegates. Speakers include Dr Penny Kechagioglou Dr Rob Verkerk PhD Patricia Peat Mark Sean Taylor Dr Britt Cordi PhD And the Conference will be opened and closed by Robin Daly, the Yes to Life Founder and Chairman. Find out more and book you tickets now via the link below: https://lnkd.in/eaJdYpKK #yestolife #cancercharity #cancersupport #integrativecancercare #healthconference #integrativemedicine #integrativeoncology #integrativehealth

📚Celebrating ISOPP Member Publications!📚 Jill Kolesar (Lexington, United States): Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer - Cancers. Apr 2024. https://lnkd.in/gDNNM2H3 Fiorenza Enrico (Piossasco (Turin), Italy): A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL) - Frontiers in Oncology. Apr 2024. https://lnkd.in/gktXEstZ Carlo DeAngelis (Toronto, Canada), Flay Charbonneau (Toronto, Canada): 2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients - Supportive Care in Cancer. Apr 2024. https://lnkd.in/gnBkW7yi